1. Aggarwal, S. Targeted cancer therapies. Nat Rev Drug Discov. 2010;9:427–428.
2. Ashley, EA, Butte, AJ, Wheeler, MT, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375:1525–1535.
3. Atreja, A, Achkar, J-P, Jain, AK, Harris, CM, Lashner, BA. Using technology to promote gastrointestinal outcomes research: A case for electronic health records. Am J Gastroenterol. 2008;103:2171–2178.
4. Barker, AD, Sigman, CC, Hylton, NM, Berry, DA, Esserman, LJ. I-SPY2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86:97–100.
5. Bies, RR, Gastonguay, MR, Schwartz, SL. Mathematics for understanding disease. Clin Pharmacol Ther. 2008;83:904–908.
6. Brenner, S. Sequences and consequences. Philos Trans R Soc Lond B Biol Sci. 2010;365:207–212.
10. Guyatt, GH, Oxman, AD, Vist, GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.
11. Hornberg, JJ, Bruggeman, FJ, Westerhoff, HV, Lankelma, J. Cancer: A systems biology disease. BioSystems. 2006;83:81–90.
13. International Network of Agencies for Health Technology Assessment. HTA resources. http://www.inahta.org/HTA/ (accessed June 1, 2010).
14. Kohane, IS. The twin questions of personalized medicine: Who are you and whom do you most resemble? Genome Med. 2009;1:4.
15. Kravitz, RL, Duan, N, White, RH. N-of-1 Trials of expensive biological therapies: A third way? Arch Intern Med. 2008;168:1030–1033.
16. Leary, RJ, Kinde, I, Diehl, F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010;2:20ra14.
17. Lunshof, JE. Personalized medicine: How much can we afford? A bioethics perspective. Per Med. 2005;2:43–47.
18. Murgo, AJ, Kumar, S, Rubinstein, L, et al. Designing phase 0 cancer clinical trials. Clin Cancer Res. 2008;14:3675–3682.
19. Ogilvie, D, Craig, P, Griffin, S, Macintyre, S, Wareham, NJ. A translational framework for public health research. BMC Public Health. 2009; 9:116–125.
20. Retel, VP, Bueno-de-Mesquita, JM, Hummel, MJM, et al. Constructive technology assessment (CTA) as a tool in coverage with evidence development: The case of the 70-gene prognosis signature for breast cancer diagnostics. Int J Technol Assess Health Care. 2009;25:73–83.
21. Rogowski, WH, Hartz, SC, John, JH. Clearing up the hazy road from bench to bedside: A framework for integrating the fourth hurdle into translational medicine. BMC Health Serv Res. 2008;8:194.
22. Rosenkötter, N, Vondeling, H, Blancquaert, I, et al. The contribution of health technology assessment, health needs assessment, and health impact assessment to the assessment and translation of technologies in the field of public health genomics. Public Health Genomics. 2011;14:43–52.
23. Samani, NJ, Tomaszewski, M, Schunkert, H. The personal genome—the future of personalized medicine? Lancet. 2010;375:1497–1498.
24. Schulman, K, Valverde Vidal, A, Ackerly, DC. Personalized medicine and disruptive innovation: Implications for technology assessment. Genet Med. 2009;11:577–581.
25. Shabo, A. Clinical genomics data standards for pharmacogenetics and pharmacogenomics. Pharmacogenomics. 2006;7:247–253.
26. Westerhoff, HV, Palsson, BO. The evolution of molecular biology into systems biology. Nat Biotechnol. 2004;10:1249–1252.